On the same day, 3 pharmaceutical companies announced changes in executives

In the market environment such as medical reform and centralized procurement, the flow of executives in the pharmaceutical industry has been very frequent in recent years, with 30 executives leaving in March alone
.
Recently, the flow of executives of pharmaceutical companies is still very turbulent; on the same day, three pharmaceutical companies announced new personnel appointments
.
On April 20, Merck announced that Joseph Romanelli will return to Merck to lead Merck's Human Health International Department and join the company's executive committee, reporting directly to Merck's global president and CEO Robert Dai.
Davis), appointments are effective August 1, 2022
.
It is understood that Luo Wanli joined Jixing Pharmaceutical as the company's chief executive officer and a member of the board of directors in July last year
.
On the same day, Junshi Bio announced that it nominated Dr.
Zou Jianjun as the company's executive director, appointed him as the company's deputy general manager and served as the global R&D president, responsible for the company's global research and development
.
It is understood that Hengrui Medicine just issued an announcement on April 12, announcing the departure of Chief Medical Officer (CMO) and Deputy General Manager Zou Jianjun
.
In addition, Luoxin Pharmaceutical also issued an announcement stating that Du Enbin applied for his resignation as a representative of securities affairs due to personal reasons.
The resignation application will take effect from the day the resignation report is served on the company's board of directors.
After resignation, he will no longer hold any positions in the company and its subsidiaries
.
At the same time, the company agreed to appoint Zhu Xueyun as the new securities affairs representative, and the term of office will start from the date of deliberation and approval by the board of directors and end on the date of the expiration of the term of office of the fourth session of the board of directors
.
It is reported that since July 2020, Zhu Xueyun has been the securities affairs manager of Luoxin Pharmaceutical Group Co.
,
Ltd.
Although the flow of executives has become the norm in recent years, it is worth noting that among a large number of companies, many executives of multinational pharmaceutical companies have returned to multinational pharmaceutical companies after they have flowed to local companies
.
It is understood that in Merck China, there have been cases of senior executives returning after leaving office, such as Li Zhengqing, general manager of Merck China R&D Center, who left Merck in 2019 to join Ascletis Pharma as chief medical officer and R&D president of Greater China.
But in the same year, he returned to MSD as the head of MSD China R&D Center.

.
In addition, not long ago, Roche also announced the news of the return of executives
.
On February 22, Roche Pharmaceuticals announced that Mr.
Qian Wei will be appointed as General Manager of Roche's China Customer Interaction Business Model - Oncology Field, responsible for Roche's oncology field
.
Qian Wei left Roche at the end of June 2021, later chose to join Junshi Bio, and now returns to Roche
.
Behind the return of a group of local pharmaceutical executives to multinational pharmaceutical companies, the industry believes that it is mainly determined by multi-level and complex decision-making
.
At first, executives of multinational pharmaceutical companies left to join domestic start-up pharmaceutical companies or start businesses, which was caused by the vigorous development of the biotechnology industry
.
However, after foreign executives take up jobs in local pharmaceutical companies, they are likely to be "unacceptable" in terms of values, culture, capital, etc.
, so they make the decision to leave
.
Therefore, for local pharmaceutical companies, although the company may have recruited high-level talents, how to retain them will be a question worth thinking about
.
In general, most multinational pharmaceutical companies are currently in a period of strategic adjustment, while local pharmaceutical companies are also ushering in a period of transformation and breakthrough.
The talent competition between the two sides will definitely intensify, and the flow of executives will become more frequent
.
In the future, how to attract more and more professional talents in the competition will become a compulsory course for local pharmaceutical companies in the period of transformation and upgrading
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.